mTORC1 signaling and IL-17 expression: Defining pathways and possible therapeutic targets

Wenkai Ren; Jie Yin; Jielin Duan; Gang Liu; Bie Tan; Guan Yang; Guoyao Wu; Fuller W. Bazer; Yuanyi Peng; Yulong Yin

doi:10.1002/eji.201545886

mTORC1 signaling and IL-17 expression: Defining pathways and possible therapeutic targets

Wenkai Ren, Jie Yin, Jielin Duan, Gang Liu, Bie Tan, Guan Yang, Guoyao Wu, Fuller W. Bazer, Yuanyi Peng, Yulong Yin^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 62 - Review of books or of software (or similar publications/items) › peer-review

82 Citations (Scopus)

Abstract

IL-17 mediates immune responses against extracellular pathogens, and it is associated with the development and pathogenesis of various autoimmune diseases. The expression of IL-17 is regulated by various intracellular signaling cascades. Recently, it has been shown that mechanistic target of rapamycin (mTOR) signaling, comprised mainly of mTORC1 signaling, plays a critical role in IL-17 expression. Here, we review the current knowledge regarding mechanisms by which mTORC1 regulates IL-17 expression. mTORC1 positively modulates IL-17 expression through several pathways, i.e. STAT3, -HIF-1α, -S6K1, and -S6K2. Amino acids (AAs) also regulate IL-17 expression by being the energy source for Th17 cells, and by activating mTORC1 signaling. Altogether, the AA-mTORC1-IL-17 axis has broad therapeutic implications for IL-17-associated diseases, such as EAE, allergies, and colitis.

Original language	English
Pages (from-to)	291-299
Journal	European Journal of Immunology
Volume	46
Issue number	2
DOIs	https://doi.org/10.1002/eji.201545886
Publication status	Published - 1 Feb 2016
Externally published	Yes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

Research Keywords

Amino acid
HIF-1α
IL-17
mTORC1
STAT

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access Output

10.1002/eji.201545886

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{dabec87e26c044508fe87dab76d63769,

title = "mTORC1 signaling and IL-17 expression: Defining pathways and possible therapeutic targets",

abstract = "IL-17 mediates immune responses against extracellular pathogens, and it is associated with the development and pathogenesis of various autoimmune diseases. The expression of IL-17 is regulated by various intracellular signaling cascades. Recently, it has been shown that mechanistic target of rapamycin (mTOR) signaling, comprised mainly of mTORC1 signaling, plays a critical role in IL-17 expression. Here, we review the current knowledge regarding mechanisms by which mTORC1 regulates IL-17 expression. mTORC1 positively modulates IL-17 expression through several pathways, i.e. STAT3, -HIF-1α, -S6K1, and -S6K2. Amino acids (AAs) also regulate IL-17 expression by being the energy source for Th17 cells, and by activating mTORC1 signaling. Altogether, the AA-mTORC1-IL-17 axis has broad therapeutic implications for IL-17-associated diseases, such as EAE, allergies, and colitis.",

keywords = "Amino acid, HIF-1α, IL-17, mTORC1, STAT",

author = "Wenkai Ren and Jie Yin and Jielin Duan and Gang Liu and Bie Tan and Guan Yang and Guoyao Wu and Bazer, {Fuller W.} and Yuanyi Peng and Yulong Yin",

note = "Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].",

year = "2016",

month = feb,

day = "1",

doi = "10.1002/eji.201545886",

language = "English",

volume = "46",

pages = "291--299",

journal = "European Journal of Immunology",

issn = "0014-2980",

publisher = "Wiley-VCH Verlag GmbH",

number = "2",

}

TY - JOUR

T1 - mTORC1 signaling and IL-17 expression

T2 - Defining pathways and possible therapeutic targets

AU - Ren, Wenkai

AU - Yin, Jie

AU - Duan, Jielin

AU - Liu, Gang

AU - Tan, Bie

AU - Yang, Guan

AU - Wu, Guoyao

AU - Bazer, Fuller W.

AU - Peng, Yuanyi

AU - Yin, Yulong

N1 - Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

PY - 2016/2/1

Y1 - 2016/2/1

N2 - IL-17 mediates immune responses against extracellular pathogens, and it is associated with the development and pathogenesis of various autoimmune diseases. The expression of IL-17 is regulated by various intracellular signaling cascades. Recently, it has been shown that mechanistic target of rapamycin (mTOR) signaling, comprised mainly of mTORC1 signaling, plays a critical role in IL-17 expression. Here, we review the current knowledge regarding mechanisms by which mTORC1 regulates IL-17 expression. mTORC1 positively modulates IL-17 expression through several pathways, i.e. STAT3, -HIF-1α, -S6K1, and -S6K2. Amino acids (AAs) also regulate IL-17 expression by being the energy source for Th17 cells, and by activating mTORC1 signaling. Altogether, the AA-mTORC1-IL-17 axis has broad therapeutic implications for IL-17-associated diseases, such as EAE, allergies, and colitis.

AB - IL-17 mediates immune responses against extracellular pathogens, and it is associated with the development and pathogenesis of various autoimmune diseases. The expression of IL-17 is regulated by various intracellular signaling cascades. Recently, it has been shown that mechanistic target of rapamycin (mTOR) signaling, comprised mainly of mTORC1 signaling, plays a critical role in IL-17 expression. Here, we review the current knowledge regarding mechanisms by which mTORC1 regulates IL-17 expression. mTORC1 positively modulates IL-17 expression through several pathways, i.e. STAT3, -HIF-1α, -S6K1, and -S6K2. Amino acids (AAs) also regulate IL-17 expression by being the energy source for Th17 cells, and by activating mTORC1 signaling. Altogether, the AA-mTORC1-IL-17 axis has broad therapeutic implications for IL-17-associated diseases, such as EAE, allergies, and colitis.

KW - Amino acid

KW - HIF-1α

KW - IL-17

KW - mTORC1

KW - STAT

UR - http://www.scopus.com/inward/record.url?scp=84956818610&partnerID=8YFLogxK

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-84956818610&origin=recordpage

U2 - 10.1002/eji.201545886

DO - 10.1002/eji.201545886

M3 - RGC 62 - Review of books or of software (or similar publications/items)

C2 - 26558536

SN - 0014-2980

VL - 46

SP - 291

EP - 299

JO - European Journal of Immunology

JF - European Journal of Immunology

IS - 2

ER -

mTORC1 signaling and IL-17 expression: Defining pathways and possible therapeutic targets

Abstract

Bibliographical note

Research Keywords

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this